0.00Open6.92Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover0.00%IV-0.18%PremiumJul 19, 2024Expiry Date6.93Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Biomea Fusion Stock Discussion
The pause on clinical trials seems to be a result of the explosion of industry regulations in recent years. From 2022 through 2024, the FDA has implemented "additional steps" to clinical trials, including bringing in outside agencies to help with oversight.
Red tape and bureaucracy, not BEMA, caused this pause. All the research I've done shows the pause was premature and overly cautious.
No comment yet